Bulumtatug fuvedotin not checked
Mabwell · 9MW2821
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-tug: unmodified immunoglobulins WHO name stem
- How it’s given
- “1.25mg/kg of 9MW2821 by intravenous infusion on days 1, 8 and 15 of every 28-day cycle”In the company’s words, NCT06196736 on ClinicalTrials.gov
- Tested for
- Urothelial Carcinoma (3 trials), Advanced Urothelial Carcinoma (2 trials), Cervical Cancer, Locally Advanced or Metastatic Triple-negative Breast Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Urothelial Carcinoma of the Renal Pelvis and Ureter, Triple-Negative Breast Cancer and 3 more
- Main trialPhase 3
- “The purpose of this study was to compare the antitumor activity of 9MW2821 and chemotherapy in participants with locally advanced or metastatic urothelial cancer previously treated with PD-(L)1 inhibitor and platinum-containing chemotherapy.”In the company’s words, NCT06196736 on ClinicalTrials.gov
- Other names
- 9MW2821
Other drugs for Urothelial Carcinoma
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- Cretostimogene GrenadenorepvecCG Oncology, Inc. · Phase 3
- Disitamab vedotinPfizer · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- Disitamab VedotinRemeGen · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
Coming up7
- 31 DecPhase 1/2 trial completes · ClinicalTrials.gov
- 1 May 2027Phase 1/2 trial completes · ClinicalTrials.gov
- May 2027Phase 1 trial completes · ClinicalTrials.gov
- Sep 2027Phase 3 trial completes · ClinicalTrials.gov
- 9 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- 31 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials13
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Sep 2026 | A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer | |
| Phase 3Recruiting | Sep 2027 | 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer | |
| Phase 3Recruiting | 9 Dec 2027 | A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer | |
| Phase 3Not yet recruiting | Dec 2027 | A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer | |
| Phase 2Recruiting | Jun 2026 | 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma | |
| Phase 2Recruiting | Jul 2026 | A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer | |
| Phase 2Recruiting | 31 Dec 2027 | 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer | |
| Phase 1/2Not yet recruiting | Apr 2026 | A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors | |
| Phase 1/2Recruiting | 31 Dec 2026 | 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer | |
| Phase 1/2Not yet recruiting | 1 May 2027 | 9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors | |
| Phase 1Recruiting | May 2027 | A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs | |
| Phase 1/2Unknown | Dec 2025 | A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors | |
| Phase 1Unknown | 31 Dec 2024 | A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026